Clinical Trials/NCT02279953

NCT02279953

Completed

Phase 3

An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

H. Lundbeck A/S17 sites in 5 countries151 target enrollmentOctober 2014

ConditionsMajor Depressive Disorder

InterventionsVortioxetine 10-20 mg Placebo SSRI

DrugsVortioxetine 10-20 mg Placebo SSRI

Overview

Phase: Phase 3
Intervention: Vortioxetine 10-20 mg
Conditions: Major Depressive Disorder
Sponsor: H. Lundbeck A/S
Enrollment: 151
Locations: 17
Primary Endpoint: Change in Digit Symbol Substitution Test (DSST): number of correct symbols
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning and attention) in patients who are in partial or full remission from their Major Depressive Episode (MDE).

Registry

clinicaltrials.gov

Start Date

October 2014

End Date

April 2016

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

H. Lundbeck A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The patient has achieved either partial (some symptoms of a MDE are present but full criteria are not met) or full remission of major depressive disorder (MDD), diagnosed according to DSM-IV-TR™.
•The patient has HAMD-17 total score ≤
•The patient has received SSRI monotherapy for the MDE from which the patient is currently in full or partial remission for ≥12 weeks at licensed doses and been on stable dose ≥8 weeks prior to Screening Visit.
•The patient has ≥50% response to current SSRI treatment (Antidepressant Treatment Response Questionnaire \[ATRQ\]).
•The patient has a PDQ-D total score \>
•The patient is a man or woman, aged ≥18 and ≤65 years.

Exclusion Criteria

•The patient has a score ≥70 on the DSST (numbers of correct symbols) at the Baseline Visit.
•The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit.
•The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
•The patient is diagnosed with reading disability (dyslexia).
•The patient has a history of lack of response to previous adequate treatment with vortioxetine.
•The patient has any current psychiatric disorder or Axis I disorder (according to DSM-IV-TR™ criteria) other than MDD, as assessed using Mini International Neuropsychiatric Interview (MINI).
•The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of the depressive episode from which the patient is currently in full or partial remission (DSM-IV-TR™ criteria).
•The patient has borderline, schizotypal, schizoid, paranoid, histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
•The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
•The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).

Arms & Interventions

Vortioxetine 10-20 mg

daily, encapsulated, orally

Intervention: Vortioxetine 10-20 mg

Vortioxetine 10-20 mg

daily, encapsulated, orally

Intervention: Placebo

Vortioxetine 10-20 mg + SSRI

daily, encapsulated, orally

Intervention: Vortioxetine 10-20 mg

Vortioxetine 10-20 mg + SSRI

daily, encapsulated, orally

Intervention: SSRI

SSRI

licensed doses, encapsulated, orally

Intervention: Placebo

SSRI

licensed doses, encapsulated, orally

Intervention: SSRI

Outcomes

Primary Outcomes

Change in Digit Symbol Substitution Test (DSST): number of correct symbols

Time Frame: Baseline to Week 8

Secondary Outcomes

Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning(Baseline to Week 8)
Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed(Baseline to Week 8)
Change in Trail Making Test (TMT) score: TMT-A; speed of processing(Baseline to Week 8)
Change in TMT score: TMT-B; executive functioning(Baseline to Week 8)
Change in reaction time score: Choice Reaction Time (CRT); attention(Baseline to Week 8)
Change in STROOP: congruent score; speed of processing(Baseline to Week 8)
Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score(Baseline to Week 8)
Change in Hamilton Depression Rating Scale-17 (HAMD-17) total score(Baseline to Week 8)
Change in Rey Auditory Verbal Learning Test (RAVLT) score: memory (delayed recall) and learning [acquisition])(Baseline to Week 8)
Change in Clinical Global Impression - Severity of Illness (CGI-S)(Baseline to Week 8)
Clinical Global Impression - Global Improvement (CGI-I) score(Week 8)
Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score(Baseline to Week 8)
Number of adverse events(Baseline to Week 12)
Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions (1, 2, 3, 4 and 7)(Baseline to Week 8)